Fifer Sheila K, Buesching Don P, Henke Curtis J, Potter Lori P, Mathias Susan D, Schonfeld Warren H, Patrick Donald L
The Lewin Group, San Francisco, CA, USA.
Value Health. 2003 Jan-Feb;6(1):40-50. doi: 10.1046/j.1524-4733.2003.00148.x.
Certain anxious/depressed primary care patients decrease medical utilization after mental health treatment. Previous research has established demo-graphic and medical comorbidities as distinguishing these patients. We asked whether characteristics such as symptom severity, somatization, or health-related quality of life (HRQoL) could also distinguish patients who reduce or increase primary care utilization after mental health care.
Primary care patients in a mixed-model HMO were screened for untreated anxiety with and without depression, using the Symptom Checklist (SCL-90-R) and medical records abstractions, and also for HRQoL (SF-36). We identified 165 symptomatic patients who subsequently received mental health treatment and then defined two subgroups: 1) offset patients (reduced medical utilization the year after initiation of mental health treatment) (N=97); and 2) no-offset patients (increased utilization) (N =68).
Three HRQoL domains (general health perceptions, physical functioning, and role functioning- physical) predicted increased offset savings in the year after initiation of mental health treatment. Each point of improved functioning in these domains was associated with 4 dollars to 10 dollars of additional offset savings. Somatization-related comorbidities were predictive of greater additional costs (230 dollars).
Using models to predict individual patient costs, we found that HRQoL and somatic comorbidities did not predict by anxiety/depression symptom severity or medical comorbidities, but by increasing or decreasing utilization after mental health care. Patients with higher functioning levels and no somatic comorbidities were most likely to reduce utilization. These findings support growing evidence for the need of inclusion of reliable indicators of somatization and patients' functioning in offset research and inpatient care.
某些焦虑/抑郁的初级保健患者在接受心理健康治疗后会减少医疗服务的使用。先前的研究已确定人口统计学特征和医学合并症是区分这些患者的因素。我们想了解症状严重程度、躯体化或健康相关生活质量(HRQoL)等特征是否也能区分在接受心理健康治疗后初级保健服务使用减少或增加的患者。
使用症状自评量表(SCL - 90 - R)和病历摘要,对混合模式健康维护组织(HMO)中的初级保健患者进行未治疗的焦虑(伴或不伴抑郁)筛查,并对HRQoL进行评估(SF - 36)。我们确定了165名有症状的患者,他们随后接受了心理健康治疗,然后将其分为两个亚组:1)抵消组患者(心理健康治疗开始后一年医疗服务使用减少)(N = 97);2)无抵消组患者(医疗服务使用增加)(N = 68)。
三个HRQoL领域(总体健康感知、身体功能和角色功能 - 身体)预测了心理健康治疗开始后一年抵消节省费用的增加。这些领域中功能每改善一分,额外的抵消节省费用就增加4美元至10美元。与躯体化相关的合并症预示着更高的额外费用(230美元)。
通过使用模型预测个体患者费用,我们发现HRQoL和躯体合并症不是由焦虑/抑郁症状严重程度或医学合并症预测的,而是由心理健康治疗后使用的增加或减少来预测的。功能水平较高且无躯体合并症的患者最有可能减少医疗服务的使用。这些发现支持了越来越多的证据,表明在抵消研究和住院治疗中需要纳入躯体化和患者功能的可靠指标。